Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

NCT03167151 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped The study failed to recruit within the permitted timeframe

Conditions

Non-muscle Invasive Bladder Cancer (NMIBC)

Interventions

DRUG: Pembrolizumab

Sponsor

University of Oxford

Collaborators

[object Object]